SCHEMBL3775340

SCHEMBL3775340

CCOc1cc(CN2CCC(Nc3ncc(OS(C)(=O)=O)cn3)CC2)cc(OCC)c1-c1ccc(F)cc1

nearest known ligand 0.58

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SSTR5 P35346 20/20 0.58
KCNH2 Q12809 7/20 0.57
SSTR3 P32745 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2419823 0.91 SSTR5 (0.64) SSTR5KCNH2SSTR3
SCHEMBL3774539 0.89 SSTR5 (0.54) SSTR5KCNH2
SCHEMBL3782938 0.85 SSTR5 (0.61) SSTR5KCNH2SSTR3
SCHEMBL3779134 0.85 SSTR5 (0.52) SSTR5KCNH2
SCHEMBL3782770 0.85 SSTR5 (0.57) SSTR5KCNH2SSTR3
SCHEMBL3775575 0.85 SSTR5 (0.55) SSTR5KCNH2SSTR3
SCHEMBL2421955 0.83 SSTR5 (0.64) SSTR5KCNH2SSTR3
SCHEMBL1121556 0.83 SSTR5 (0.61) SSTR5KCNH2
SCHEMBL3780630 0.83 SSTR5 (0.54) SSTR5KCNH2SSTR3
SCHEMBL2954727 0.80 SSTR5 (0.67) SSTR5KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855194-B2 Pyrimidine, quinazoline, pteridine and triazine derivatives HOFFMANN-LA ROCHE INC. (US) 2010-12-21 US disclosed
EP-2001867-B1 PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2009-07-01 EP disclosed
US-20070225271-A1 Pyrimidine, quinazoline, pteridine and triazine derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225271-A1 Pyrimidine, quinazoline, pteridine and triazine derivatives SSTR5, SSTR3, SSTR1 SSTR5 1/4885KCNH2 1172/4885SSTR3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.